title: [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
abstract: A 67-year-old woman underwent radical nephrectomy (clear cell carcinoma, G2＞3, pT2b) for left renal cancer with pulmonary metastasis. After interferon-α treatment for 7 months, right iliac bone metastasis occurred. Pulmonary and right ileac bone metastases became larger after 4 months of first sunitinib administration. Replacement by everolimus treatment was not effective. After 6 months of sunitinib rechallenge therapy, pulmonary metastasis disappeared and right ileac bone metastasis became smaller. However, 1 month later, right costal and left femoral metastases occurred. She was kept on sunitinib treatment, and there were no changes in these metastases for 1 year. However, it was difficult to continue sunitinib treatment because of side effects, resulting in growth of metastases. Costal and femoral metastases showed a partial response to axtinib treatment given thereafter. Tyrosine kinase inhibitor rechallenge therapy had potential benefits and was tolerated in selected metastatic renal cell carcinoma patients.
authors.affiliation: The Department of Urology, Souka Municiple Hospital.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yoshinaga
authors.affiliation: The Department of Urology, Souka Municiple Hospital.
authors.forename: Shigeyoshi
authors.initials: S
authors.lastname: Kamata
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009392:Nephrectomy; D011758:Pyrroles / Q000627:therapeutic use*; D012008:Recurrence; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib